Phase 3 Readout

SNDX: Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination With Inten

Name: Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination With Inten
Start: 2031-01-01
End: 2031-01-01

January 1, 2031 · revumenib. BioSniper AI can trace the company-impact path without requiring you to write the research question.

Event date: January 1, 2031
Company: Syndax Pharmaceuticals Inc (SNDX)
Drug: revumenib

BioSniper AIPage evidence connected

Prepared research question

What could this event change, and which evidence should be watched next?

Run cited research

Traceable citations · Unknowns marked

Phase 3 Readout~month

Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination With Inten

January 1, 2031

SNDX overview →

Company: Syndax Pharmaceuticals Inc (SNDX)
Drug: revumenib
Indication: Acute Myeloid Leukemias